

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

---

**SECTION 1. IDENTIFICATION**

Product name : Cefadroxil Monohydrate Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : Talcahuano 750, 6th floor, Ciudad Autonoma  
Buenos Aires, Argentina C1013AAP

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Respiratory sensitization : Category 1

**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary Statements : **Prevention:**  
P261 Avoid breathing dust.  
P284 Wear respiratory protection.  
**Response:**  
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.  
**Disposal:**  
P501 Dispose of contents/ container to an approved waste

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

disposal plant.

**Additional Labeling**

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 42 %

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 50 -< 70
Cefadroxil	66592-87-8	>= 30 -< 50
Magnesium stearate	557-04-0	>= 1 -< 5

**SECTION 4. FIRST AID MEASURES**

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.
In case of skin contact	: Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome). Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

---

- Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Sodium oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air.  
Add excess liquid to allow the material to enter into solution.  
Soak up with inert absorbent material.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

**Cefadroxil Monohydrate Formulation**

Version 3.0      Revision Date: 14.04.2025      SDS Number: 10679099-00007      Date of last issue: 28.09.2024  
Date of first issue: 06.05.2022

determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**SECTION 7. HANDLING AND STORAGE**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	CMP	10 mg/m <sup>3</sup>	AR OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Cefadroxil	66592-87-8	TWA	500 mcg/m <sup>3</sup> (OEB 2)	Internal
Further information: RSEN				
Magnesium stearate	557-04-0	CMP	10 mg/m <sup>3</sup>	AR OEL
Further information: A4 - Not classifiable as a human carcinogen				
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH

## Cefadroxil Monohydrate Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 10679099-00007      Date of last issue: 28.09.2024  
 Date of first issue: 06.05.2022

		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH
--	--	--	---------------------	-------

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Personal protective equipment**

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Eye protection** : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance** : powder

**Color** : white

**Odor** : No data available

**Odor Threshold** : No data available

**pH** : No data available

**Melting point/freezing point** : No data available

**Initial boiling point and boiling range** : No data available

**Flash point** : Not applicable

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

---

Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks.

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

Incompatible materials	:	Avoid dust formation.
Hazardous decomposition products	:	Oxidizing agents
	:	No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5,8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg

**Cefadroxil:**

Acute oral toxicity	:	LD50 (Rat): > 8.000 mg/kg  LD50 (Mouse): > 7.000 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 6.000 mg/kg Application Route: Intraperitoneal  LD50 (Mouse): > 7.000 mg/kg Application Route: Intraperitoneal  LD50 (Rat): > 1.000 mg/kg Application Route: Intravenous  LD50 (Mouse): > 1.500 mg/kg Application Route: Intravenous

**Magnesium stearate:**

Acute oral toxicity	:	LD50 (Rat): > 2.000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg Remarks: Based on data from similar materials

## Cefadroxil Monohydrate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Magnesium stearate:**

Species	:	Rabbit
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Magnesium stearate:**

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:****Cefadroxil:**

Result	:	Sensitizer
--------	---	------------

**Magnesium stearate:**

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
	:	Result: negative
	:	Test Type: In vitro mammalian cell gene mutation test
	:	Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo)



**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Cefadroxil:**

Effects on fertility : Test Type: Fertility  
Species: Mouse  
Application Route: Intraperitoneal  
Fertility: NOAEL: 400 mg/kg body weight  
Result: No adverse effects.

## Cefadroxil Monohydrate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 500 mg/kg body weight  
Result: No adverse effects.

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
NOAEL :  $\geq 9.000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Cefadroxil:**

Species : Mouse  
NOAEL : 200 mg/kg  
Application Route : Oral  
Exposure time : 14 W  
Target Organs : Prostate, male reproductive organs, Liver, Adrenal gland

Species : Rat  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 26 W  
Target Organs : Kidney

Species : Rat  
LOAEL :  $> 316$  mg/kg  
Application Route : Oral  
Exposure time : 26 W

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

Target Organs	: Kidney
Species	: Dog
LOAEL	: 200 mg/kg
Exposure time	: 26 W
Target Organs	: Blood, Liver
Remarks	: May cause damage to organs.

**Magnesium stearate:**

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Cefadroxil:**

Inhalation	: Symptoms: Nausea, Vomiting, vaginitis, Headache, Dizziness, dry mouth, Fatigue, constipation, colitis, Gastrointestinal disturbance
------------	---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--

**Cefadroxil:****Ecotoxicology Assessment**

Acute aquatic toxicity	: Toxic effects cannot be excluded
Chronic aquatic toxicity	: Toxic effects cannot be excluded

**Magnesium stearate:**

Toxicity to fish	: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h

## Cefadroxil Monohydrate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

		Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility.
		NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Cellulose:**

Biodegradability	:	Result: Readily biodegradable.
------------------	---	--------------------------------

**Magnesium stearate:**

Biodegradability	:	Result: Not biodegradable Remarks: Based on data from similar materials
------------------	---	--

**Bioaccumulative potential****Components:****Magnesium stearate:**

Partition coefficient: n-octanol/water	:	log Pow: > 4
--	---	--------------

**Mobility in soil**

No data available

**Other adverse effects**

No data available

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

Not applicable

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**SECTION 16. OTHER INFORMATION**

Revision Date	:	14.04.2025
Date format	:	dd.mm.yyyy

**Further information**

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD

## Cefadroxil Monohydrate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

compile the Material Safety  
Data SheeteChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
AR OEL	:	Argentina. Occupational Exposure Limits
ACGIH / TWA	:	8-hour, time-weighted average
AR OEL / CMP	:	TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET



## Cefadroxil Monohydrate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	10679099-00007	Date of first issue: 06.05.2022

---

AR / Z8